JAK inhibition in myelofibrosis: how to sequence treatment in this new era of multiple options

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Myelofibrosis management has advanced with JAK inhibitors.
• Ruxolitinib, the first JAK inhibitor, has limitations including myelosuppression and loss of response.
• Recent approvals expand JAK inhibitor therapy for myelofibrosis.

Purpose of the Study:

• To review the evolving landscape of JAK inhibitor therapy in myelofibrosis.
• To highlight new treatment options and their specific benefits.
• To identify remaining unmet needs in myelofibrosis management.

Main Methods:

• Review of recent clinical trial data and regulatory approvals for JAK inhibitors in myelofibrosis.
• Comparative analysis of efficacy and safety profiles of available agents.
• Discussion of treatment guidelines and future directions.

Main Results:

• Fedratinib shows efficacy as a front-line and salvage therapy.
• Pacritinib provides an option for patients with severe thrombocytopenia.
• Momelotinib demonstrates responses in spleen, symptoms, and anemia.

Conclusions:

• The availability of multiple JAK inhibitors marks significant progress in myelofibrosis treatment.
• New agents address specific patient populations and unmet needs, such as anemia.
• Achieving clinical and molecular remissions remains the primary objective in myelofibrosis therapy.